ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

318
Analysis
Health CareChina
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
15 Jul 2024 00:28

Merger Arb Mondays (15 Jul) - China TCM, Canvest, Henlius, Hollysys, Second Chance, Anasarda, Rex

This week, the highest gross spreads are HEC Pharma (134.8%), China TCM (32.2%), Canvest (13.4%), A8 New Media (12.5%), Asia Cement (11.8%), GA...

Logo
589 Views
Share
bullishTimee
14 Jul 2024 07:12

Weekly Deals Digest (14 Jul) - Timee, ASICS, Honda, Kokusai, Sanil, Canvest, Henlius, HKTV, Rex

Last week, notable developments occurred in Event-Driven (Canvest Environmental, Henlius, HKTV, Rex Minerals, Second Chance) and ECM (ASICS, Honda,...

Logo
488 Views
Share
14 Jul 2024 07:00

Last Week in Event SPACE: Toyota, Asia Cement, Hanwha Corp, Kokusai Electric, Keisei Electric

The weekend is here! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed...

Logo
537 Views
Share
bullishAltium Ltd
13 Jul 2024 15:00

(Mostly) Asia-Pac M&A: Second Chance Properties, Shinsung Tongsang, Rex Minerals, Canvest, Altium

This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...

Logo
606 Views
Share
12 Jul 2024 09:36

Henlius (2696 HK): Here Comes The Scrip Option

This is trading wide-ish at 8.8%/28.8% currently (assuming mid-Nov payment), ostensibly due to the timing on the regulatory approvals - TCM (570...

Logo
618 Views
Share
x